Navigation Links
Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
Date:8/12/2009

PALO ALTO, Calif., Aug. 12 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been granted CE Mark approval by the European Notified Body, G-Med.

"The technology of the Advantage VRD is an important demonstration of Nfocus design talent and teamwork," noted company Chairman, Eric P. Milledge. "The technical platform behind this device will pave the way for future Nfocus neurovascular products currently in development."

The CardioVasc Advantage(TM) Vascular Reconstruction Device has been cleared in Europe for the treatment of coronary artery perforations, aneurysms and saphenous vein graft lesions. Today, these critical pathologies are most frequently treated through less-invasive endovascular procedures. The Advantage VRD was designed to provide clinical benefits in these exacting procedures performed in small vessels.

"The Advantage VRD is a significant advance over previous small-vessel stent-grafts," said Martin S. Dieck, President and CEO.

"The Advantage VRD has greatly improved flexibility and a smaller crossing profile when compared to competitive devices. The European CE Mark approval gives Nfocus the ability to market this advanced system for the treatment of serious coronary vascular indications. The device is capable of attaining more distal placement with less vessel trauma due to its innovative design."

About Nfocus Neuromedical, Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices) . Backed by premier venture investors, the Company's primary mission is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.

To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the Nfocus website: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org


'/>"/>
SOURCE Nfocus Neuromedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
2. National Healthcare Providers Select onFocus epm(TM) To Help Ensure Success on Financial and Strategic Objectives
3. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
6. China Sky One Medical, Inc. Obtains Renewal of GMP Certificate
7. RainEarth Obtains Patent Approvals for Its Core Technology
8. China Sky One Medical, Inc. Obtains Production License Renewal for Sumei Slim Patch
9. China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium Eye Drops
10. Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
11. Hard To Treat Diseases (HTDS) Obtains HAS Certificate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: